Teplizumab Preserves Beta Cell Function in Youth with Newly Diagnosed Type 1 Diabetes: Insights from the PROTECT Trial Per-Protocol Analysis
Posted inDiabetes & Endocrinology news Pediatrics

Teplizumab Preserves Beta Cell Function in Youth with Newly Diagnosed Type 1 Diabetes: Insights from the PROTECT Trial Per-Protocol Analysis

The PROTECT trial's per-protocol analysis confirms teplizumab's efficacy in preserving beta cell function, reducing insulin needs, and improving glycemic control in children and adolescents newly diagnosed with stage 3 type 1 diabetes, regardless of HLA subtype or autoantibody profile.